Matinas BioPharma (NYSEAMERICAN: MTNB) CEO, Jerome D. Jabbour, sits down with WSM’s Jason Lin at NYSE to discuss its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions, as well as MAT2203, the medicine to treat serious invasive fungal infections.
